Revive Therapeutics Advances Inflammatory Liver Disorders Programs for Autoimmune Hepatitis and Liver Transplantation May 31, 2022
Trade To Black Podcast: Biomedical Engineer Analyzes Potential Phase 3 Outcomes For Revive Therapeutics COVID Trial May 29, 2022
Revive Therapeutics May Seek FDA Approval To Amend Phase 3 Endpoints In Bucillamine Trial To A Symptoms Focus Apr 11, 2022
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19 Mar 29, 2022